Read by QxMD icon Read

Uterine serous cancer

Mary McGunigal, Jerry Liu, Tamara Kalir, Manjeet Chadha, Vishal Gupta
OBJECTIVES: High-risk histology including UPSC, CC, and high-grade (G3) endometrioid adenocarcinoma (EAC) have a worse prognosis compared to G1-2 EAC. It is unknown whether G3EAC outcomes are more similar to UPSC/CC or to G1-2 EAC. The purpose of this study was to compare overall survival (OS) among UPSC, CC, and G1-3 EAC, for International Federation of Gynecology and Obstetrics stages I to III. METHODS: The National Cancer Data Base was queried for patients diagnosed with International Federation of Gynecology and Obstetrics (1988 classification) Stage I-III UPSC, CC, and EAC from 1998 to 2012 who underwent surgery as definitive treatment...
October 18, 2016: International Journal of Gynecological Cancer
Amanda N Fader, James Java, Meaghan Tenney, Stephanie Ricci, Camille C Gunderson, Sarah M Temkin, Nick Spirtos, Christina L Kushnir, Michael L Pearl, Oliver Zivanovic, Krishnansu S Tewari, David O'Malley, Ellen M Hartenbach, Chad A Hamilton, Natalie S Gould, Robert S Mannel, William Rodgers, Joan L Walker
OBJECTIVES: We sought to analyze the clinicopathologic features, recurrence patterns and survival outcomes of women with high-grade uterine cancer (UC) enrolled on The Gynecologic Oncology Group (GOG) LAP2 trial. METHODS: This is a post-hoc analysis of LAP-2 patients with grade 3 endometrioid adenocarcinoma (ENDO), uterine serous (USC), clear cell (CC) and carcinosarcoma (CS). Demographics, clinicopathologic features, and recurrence patterns, were compared by histology and surgical approach...
October 12, 2016: Gynecologic Oncology
Eric S Chang, William D Baker, Charles N Landen
BACKGROUND: We report diagnosis and management of stage IV papillary serous uterine cancer with initial clinical presentation as a skin rash. CASE: A 62-year-old postmenopausal female developed an erythematous rash beginning on her right lower abdomen and progressively spreading to her left abdomen, vulva, and neck. After a trial of antibiotic treatment, biopsy of left neck and right thigh skin nodules revealed papillary serous carcinoma. Abdominopelvic tomography revealed endometrial thickening and a 5 cm left adnexal mass...
November 2016: Gynecologic Oncology Reports
Nermin Koc, Selçuk Ayas, Sevcan Arzu Arinkan
Background: The objective of this study was to compare the classical method and Sectioning and Extensively Examining the Fimbriated End Protocol (SEE-FIM) in detecting microscopic lesions in fallopian tubes with gynecological lesions. Materials and Methods: From a total of 1,118 cases, 582 with various parts of both fallopian tubes sampled in three-ring-shape sections and 536 sampled with the SEE-FIM protocol were included in this study. Pathological findings of cases with endometrial carcinoma, non-uterine pelvic malignant tumor, ovarian borderline tumors, premalignancy, and benign lesions were compared...
August 19, 2016: Journal of Pathology and Translational Medicine
Ulas Solmaz, Atalay Ekin, Emre Mat, Cenk Gezer, Askin Dogan, Alper Biler, Nuri Peker, Pinar Solmaz Hasdemir, Muzaffer Sanci
PURPOSE: Uterine papillary serous carcinoma (UPSC) is an atypical variant of endometrial carcinoma with a poor prognosis. It is commonly associated with an increased risk of extrauterine disease. The aim of this study was to investigate clinical and pathological characteristics, therapeutic methods, and prognostic factors in women with UPSC. METHODS: All patients who underwent surgery for UPSC at a single high-volume cancer center between January 1995 and December 2010 were retrospectively reviewed...
August 4, 2016: Tumori
N Mazanowska, D Rajski, B Pietrzak, P Kaminski, M Wielgos
BACKGROUND: Pathological changes of uterine adnexa are frequently encountered in patients after solid-organ transplantation. The aim of the study was to evaluate the incidence of malignancies among recipients operated with the diagnosis of adnexal tumor with or without clinical symptoms. METHODS: We retrospectively analyzed data from 146 solid-organ recipients who underwent surgery in the First Department of Obstetrics and Gynecology, Medical University of Warsaw, in the years 2000 to 2014...
June 2016: Transplantation Proceedings
Dorien Haesen, Layka Abbasi Asbagh, Rita Derua, Antoine Hubert, Stefanie Schrauwen, Yana Hoorne, Frédéric Amant, Etienne Waelkens, Anna Sablina, Veerle Janssens
Somatic missense mutations in the Ser/Thr protein phosphatase 2A (PP2A) Aα scaffold subunit gene PPP2R1A are among the few genomic alterations that occur frequently in serous endometrial carcinoma (EC) and carcinosarcoma, two clinically aggressive subtypes of uterine cancer with few therapeutic options. Previous studies reported that cancer-associated Aα mutants exhibit defects in binding to other PP2A subunits and contribute to cancer development by a mechanism of haploinsufficiency. Here we report on the functional significance of the most recurrent PPP2R1A mutations in human EC, which cluster in Aα HEAT repeats 5 and 7...
October 1, 2016: Cancer Research
Pratibha S Binder, Jeffrey F Peipert, D Kallogjeri, Rebecca A Brooks, Leslie S Massad, David G Mutch, Matthew A Powell, Premal H Thaker, Carolyn K McCourt
BACKGROUND: The incidence of endometrial cancer increases with age and is associated with medical comorbidities such as obesity and diabetes. While a few cohort studies of less than 500 patients showed an association between comorbidity and survival in endometrial cancer patients, the degree of association needs to be better described. The Adult Comorbidity Evaluation 27 (ACE-27) is a validated comorbidity instrument that provides a score (0-3) based on the number and severity of medical comorbidities...
July 22, 2016: American Journal of Obstetrics and Gynecology
Jessie Ehrisman, Angeles Alvarez Secord, Andrew Berchuck, Paula S Lee, Nicola Di Santo, Micael Lopez-Acevedo, Gloria Broadwater, Fidel A Valea, Laura J Havrilesky
OBJECTIVE: To determine the rate and performance of sentinel lymph node (SLN) mapping among women with high-risk endometrial cancers. METHODS: Patients diagnosed between 2012 and 2015 with uterine cancer of grade 3 endometrioid, clear cell, serous or carcinosarcoma histology and who underwent SLN mapping prior to full pelvic lymph node dissection were included. Subjects underwent methylene blue or ICG injection for laparoscopic (N = 16) or robotic-assisted laparoscopic (N = 20) staging...
August 2016: Gynecologic Oncology Reports
F Guidozzi
Women with a BRCA1 or BRCA2 gene mutation have substantially higher risk for developing not only breast and ovarian cancers, but also for primary peritoneal, Fallopian tube, colonic, pancreatic cancers, uterine papillary serous adenocarcinoma and malignant melanoma. The risk for ovarian cancer ranges from 39 to 49% by 70 years of age in BRCA1 mutation carriers and from 11 to 18% for those with a BRCA2 mutation, whilst breast cancer increases similarly within women who have either the BRCA1 mutation or the BRCA2 mutation, from about 20% in women in their forties, 37% by the age of 50 years, 55% by 60 years and more than 70% by the age of 70 years...
October 2016: Climacteric: the Journal of the International Menopause Society
L-C Horn, D Mayr, C E Brambs, J Einenkel, I Sändig, K Schierle
Histopathological assessment of the tumor grade and cell type is central to the management and prognosis of various gynecological malignancies. Conventional grading systems for squamous carcinomas and adenocarcinomas of the vulva, vagina and cervix are poorly defined. For endometrioid tumors of the female genital tract as well as for mucinous endometrial, ovarian and seromucinous ovarian carcinomas, the 3‑tiered FIGO grading system is recommended. For uterine neuroendocrine tumors the grading system of the gastrointestinal counterparts has been adopted...
July 2016: Der Pathologe
Catherine A Shu, Malcolm C Pike, Anjali R Jotwani, Tara M Friebel, Robert A Soslow, Douglas A Levine, Katherine L Nathanson, Jason A Konner, Angela G Arnold, Faina Bogomolniy, Fanny Dao, Narciso Olvera, Elizabeth K Bancroft, Deborah J Goldfrank, Zsofia K Stadler, Mark E Robson, Carol L Brown, Mario M Leitao, Nadeem R Abu-Rustum, Carol A Aghajanian, Joanne L Blum, Susan L Neuhausen, Judy E Garber, Mary B Daly, Claudine Isaacs, Rosalind A Eeles, Patricia A Ganz, Richard R Barakat, Kenneth Offit, Susan M Domchek, Timothy R Rebbeck, Noah D Kauff
Importance: The link between BRCA mutations and uterine cancer is unclear. Therefore, although risk-reducing salpingo-oophorectomy (RRSO) is standard treatment among women with BRCA mutations (BRCA+ women), the role of concomitant hysterectomy is controversial. Objective: To determine the risk for uterine cancer and distribution of specific histologic subtypes in BRCA+ women after RRSO without hysterectomy. Design, Setting, and Participants: This multicenter prospective cohort study included 1083 women with a deleterious BRCA1 or BRCA2 mutation identified from January 1, 1995, to December 31, 2011, at 9 academic medical centers in the United States and the United Kingdom who underwent RRSO without a prior or concomitant hysterectomy...
June 30, 2016: JAMA Oncology
M J Kanis, J Rahaman, E L Moshier, K Zakashansky, L Chuang, V Kolev
PURPOSE: To evaluate sensitivity and specificity of pre-operative and frozen section pathologic evaluation (FSA) in predicting high-risk (HR) histology endometrial cancer. MATERIALS AND METHODS: A retrospective analysis was performed on all patients diagnosed with endometrial cancer at a single institution. Medical records were abstracted for baseline characteristics, surgical reports for staging, and final histology was confirmed by a gynecologic pathologist. RESULTS: 868 patients were identified...
2016: European Journal of Gynaecological Oncology
Emiliano Cocco, Salvatore Lopez, Jonathan Black, Stefania Bellone, Elena Bonazzoli, Federica Predolini, Francesca Ferrari, Carlton L Schwab, Gulden Menderes, Luca Zammataro, Natalia Buza, Pei Hui, Serena Wong, Siming Zhao, Yalai Bai, David L Rimm, Elena Ratner, Babak Litkouhi, Dan-Arin Silasi, Masoud Azodi, Peter E Schwartz, Alessandro D Santin
BACKGROUND: Clinical options for patients harbouring advanced/recurrent uterine serous carcinoma (USC), an aggressive variant of endometrial tumour, are very limited. Next-generation sequencing (NGS) data recently demonstrated that cyclin E1 (CCNE1) gene amplification and pik3ca driver mutations are common in USC and may therefore represent ideal therapeutic targets. METHODS: Cyclin E1 expression was evaluated by immunohistochemistry (IHC) on 95 USCs. The efficacy of the cyclin-dependent kinase 2/9 inhibitor CYC065 was assessed on multiple primary USC cell lines with or without CCNE1 amplification...
July 26, 2016: British Journal of Cancer
Nisa Prueksaritanond, Wasu Chantape
BACKGROUND: Uterine papillary serous carcinoma (UPSC), clear cell carcinoma (CC), grade 3 endometrioid adenocarcinoma (G3EC), and carcinosarcoma (CS) have been identified as high-grade endometrial cancers and account for the majority of uterine cancer deaths. OBJECTIVE: To compare survival outcomes of patients with UPSC, CC, G3EC and CS in Rajavithi Hospital. MATERIAL AND METHOD: A retrospective review was performed of all patients with FIGO stage I-IV endometrial cancer in Rajavithi Hospital between 1 January 2007 and 31 December 2012...
February 2016: Journal of the Medical Association of Thailand, Chotmaihet Thangphaet
Katharine M Esselen, Kathryn L Terry, Anicka Samuel, Kevin M Elias, Michelle Davis, William R Welch, Michael G Muto, Shu-Wing Ng, Ross S Berkowitz
OBJECTIVE: To describe the clinical characteristics of patients with endosalpingiosis (ES) and examine its association with endometriosis and gynecologic malignancies. METHODS: We queried the medical record for patients who underwent gynecologic surgery (Gynecologic Surgery Cohort (GSC), n=58,161) from 1998 to 2013 at a single institution for the presence of "endosalpingiosis" (ES). Demographic and clinical characteristics were collected for patients with pathologically confirmed ES (n=838)...
August 2016: Gynecologic Oncology
Bingjian Lu, Qin Chen, Xiaofei Zhang, Lili Cheng
BACKGROUND: Serous carcinoma arising in adenomyosis and adenomyotic cyst is very rare. Only 3 serous carcinomas and 5 serous endometrial intraepithelial carcinomas (EIC) have been reported to date. METHODS: We reviewed the clinicopathological features of 2 serous carcinoma in uterine adenomyosis and 1 serous EIC in adenomyotic cyst of the cervical stump. RESULTS: Case 1 had an endometrial serous carcinoma in the uterine myometrium and the left ovary...
2016: Diagnostic Pathology
Jonathan Black, Gulden Menderes, Stefania Bellone, Carlton L Schwab, Elena Bonazzoli, Francesca Ferrari, Federica Predolini, Christopher De Haydu, Emiliano Cocco, Natalia Buza, Pei Hui, Serena Wong, Salvatore Lopez, Elena Ratner, Dan-Arin Silasi, Masoud Azodi, Babak Litkouhi, Peter E Schwartz, Peter Goedings, Patrick H Beusker, Miranda M C van der Lee, C Marco Timmers, Wim H A Dokter, Alessandro D Santin
Uterine serous carcinoma (USC) is an aggressive form of endometrial cancer. Up to 35% of USC may overexpress the HER2/neu oncogene at strong (i.e., 3+) levels by IHC while an additional 40% to 50% express HER2/neu at moderate (2+) or low (1+) levels. We investigated the efficacy of SYD985, (Synthon Biopharmaceuticals), a novel HER2-targeting antibody-drug conjugate (ADC) composed of the mAb trastuzumab linked to a highly potent DNA-alkylating agent (i.e., duocarmycin) in USC. We also compared the antitumor activity of SYD985 in head-to-head experiments to trastuzumab emtansine (T-DM1), a FDA-approved ADC, against multiple primary USC cell lines expressing different levels of HER2/neu in in vitro and in vivo experiments...
August 2016: Molecular Cancer Therapeutics
Gulden Menderes, Mitchell Clark, Alessandro D Santin
Uterine serous carcinoma (USC) is a rare but aggressive subtype of endometrial cancer. Although it represents only 10% of all endometrial cancer cases, USC accounts for up to 40% of all endometrial cancer-related recurrences and subsequent deaths. With such a dismal prognosis, there is an expanding role for novel targeted approaches in the treatment of USC. Recent whole-exome sequencing studies have demonstrated gain of function of the HER2/NEU gene, as well as driver mutations in the PIK3CA/AKT/mTOR and cyclin E/FBXW7 oncogenic pathways in a large number of USCs...
April 2016: Discovery Medicine
Thomas E Bartlett, Kantaraja Chindera, Jacqueline McDermott, Charles E Breeze, William R Cooke, Allison Jones, Daniel Reisel, Smita T Karegodar, Rupali Arora, Stephan Beck, Usha Menon, Louis Dubeau, Martin Widschwendter
The exact timing and contribution of epigenetic reprogramming to carcinogenesis are unclear. Women harbouring BRCA1/2 mutations demonstrate a 30-40-fold increased risk of high-grade serous extra-uterine Müllerian cancers (HGSEMC), otherwise referred to as 'ovarian carcinomas', which frequently develop from fimbrial cells but not from the proximal portion of the fallopian tube. Here we compare the DNA methylome of the fimbrial and proximal ends of the fallopian tube in BRCA1/2 mutation carriers and non-carriers...
2016: Nature Communications
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"